Highlights of weekly biotech stock moves

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) was up C$0.01 to C$1.42 and unchanged at $1.35 on NASDAQ last week after submitting an NDA to FDA for Solorel macimorelin (AEZS-130) to diagnose adult growth hormone deficiency (GHD).

Amarin Corp. plc (NASDAQ:AMRN) gained $0.16 (11%) to $1.57 on Friday after disclosing in its 3Q13 earnings that it began the formal process to appeal FDA's rescission of an SPA for the Phase III ANCHOR trial. The trial evaluated Vascepa icosapent ethyl in combination with statins to treat high triglycerides in patients with mixed dyslipidemia...